by Madaline Spencer | Aug 4, 2025
The U.S. Food and Drug Administration (FDA) has approved Empaveli (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients ages 12 years and older to reduce proteinuria. C3G...
by Madaline Spencer | Aug 1, 2025
The U.S. Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd; TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). It was approved for the treatment of pediatric GHD by the FDA in...
by Madaline Spencer | Aug 1, 2025
Henry Wong, MD, PhD, Dermatologist at the San Diego Veterans Hospital and the University of California San Diego (UCSD), discusses cutaneous T-cell lymphoma (CTCL). CTCL is a rare group of malignancies that attack the body’s immune lymphatic system, affecting...
by Madaline Spencer | Jul 31, 2025
The U.S. Food and Drug Administration (FDA) has approved Doptelet (avatrombopag) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients one year and older who have had insufficient response to prior therapy. ITP is a rare bleeding...
by Madaline Spencer | Jul 30, 2025
Paula Rodríguez-Ortero, MD, PhD, Hematologist at the University of Navarra, discusses results of PD-1 inhibitor combination therapy in patients with multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal...
